Shuanglin Bio-Pharmacy to use idle funds for working capital

Southern Shuanglin Bio-Pharmacy (SZSE:000403) announced its intention to utilize no more than 100 million yuan of idle raised funds to temporarily supplement its working capital. The decision, approved by the board of directors, aims to improve the efficiency of the company's fund utilization. The usage period will not exceed 12 months, starting from April 19, 2025. The original plan for funds raised in February 2021 totaled 1,599,999,984.00 yuan. As of December 31, 2024, the company has used 138,887.07 million yuan of the funds and has a balance of 24,408.45 million yuan. Shuanglin Bio-Pharmacy will ensure timely reimbursement of the funds back to the dedicated account upon maturity and will limit usage to core business operations, excluding high-risk investments.